REG-4basebio Plc: Result of AGM

4BasebioAnnouncement

28/06/2024 16:00

28 June 2024

   
     


4basebio PLC

("4basebio" or the "Company")

Annual General Meeting 2024 ("AGM")

Directorate Change

Cambridge, UK, 28 June 2024 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform announces that all of the resolutions proposed at its
Annual General Meeting held earlier today were duly passed. 

At the AGM, Hansjörg Plaggemars, a non-executive director, requested to step
down from the board due to other business commitments, which the board has
accepted with immediate effect.  The board would like to thank Mr Plaggemars
for his contribution to the Company and wishes him the best with his future
endeavours.

The Company also wishes to again draw attention to the investor meeting being
held on 2 July 2024, through the Investor Meet Company platform
at 10.00am. Investors can sign up to Investor Meet Company for free and
register interest here:

https://www.investormeetcompany.com/register-investor

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC Heikki Lanckriet                                                            +44 (0)12 2396 7943  
 Nominated Adviser        Cairn Financial Advisers LLP Jo Tuner / Sandy Jamieson          +44 (0)20 7213 0880  
 Broker    Cavendish Capital Markets Limited Geoff Nash / Charlie Beeson / Nigel Birks    +44 (0)20 7220 0500  
 Lionsgate Communications (Media Enquiries) Jonathan Charles                              +44 (0)77 91892509   

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved